Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia

Article Oncology

Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia

Amy Moskop et al.

Summary: CAR T-cell therapy has shown successful application in patients with KMT2Ar infant ALL, offering potential efficacy for patients with extramedullary disease.

PEDIATRIC BLOOD & CANCER (2021)

Add to Collection

Meeting Abstract Hematology

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Adam J. Lamble et al.

BLOOD (2021)

Add to Collection

Article Oncology

Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol

Janine Stutterheim et al.

Summary: MRD levels are predictive of outcomes in infant acute lymphoblastic leukemia, helping to guide treatment interventions.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial

Patrick A. Brown et al.

Summary: In children, adolescents, and young adults with high- and intermediate-risk first relapse of B-ALL, postreinduction treatment with blinatumomab compared with chemotherapy, followed by transplant, did not result in a statistically significant difference in disease-free survival. However, study interpretation is limited by early termination with possible underpowering for the primary end point.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia A Randomized Clinical Trial

Franco Locatelli et al.

Summary: This study compared the effects of blinatumomab with consolidation chemotherapy as a third consolidation block before allogeneic hematopoietic stem cell transplant in children with high-risk first-relapse B-ALL. The results showed that, compared to chemotherapy, treatment with blinatumomab significantly improved event-free survival in children with high-risk first-relapse B-ALL.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Oncology

FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631

Patrick A. Brown et al.

Summary: Adding lestaurtinib did not improve event-free survival overall for infants with KMT2A-rearranged acute lymphoblastic leukemia, but patients who achieved potent FLT3 inhibition and had leukemia blasts sensitive to FLT3 inhibition ex vivo did benefit from the addition of lestaurtinib. Patient selection and pharmacodynamics-guided dose escalation may enhance the efficacy of FLT3 inhibition for this subtype of infant ALL.

LEUKEMIA (2021)

Add to Collection

Article Oncology

Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab

Rosemary Sutton et al.

Summary: This study reports on the Australian experience of using blinatumomab for the treatment of 24 children with relapsed/refractory B-cell acute lymphoblastic leukemia, showing a MRD response rate of 58% and 2-year survival rates. However, not all patients responded to blinatumomab, and factors such as blast genotype may affect prognosis.

PEDIATRIC BLOOD & CANCER (2021)

Add to Collection

Article Hematology